Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7465)
All Articles published online
|
Publishing Process of This Article
|
Feb 14, 2015 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ungar B, Anafy A, Yanai H, Ron Y, Yavzori M, Picard O, Fudim E, Loebstein R, Kopylov U, Chowers Y, Dotan I, Eliakim R, Ben-Horin S. Significance of low level infliximab in the absence of anti-infliximab antibodies. World J Gastroenterol 2015; 21(6): 1907-1914 [PMID: 25684959 DOI: 10.3748/wjg.v21.i6.1907] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i6/1907.htm |
| Number | Citing Articles |
| 1 |
Julianna Cheng, Zachary Hamilton, Matthew Smyth, Collin Barker, David Israel, Kevan Jacobson. Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2017; 23(10): 1762 doi: 10.1097/MIB.0000000000001212
|
| 2 |
Joana Afonso, Helena Tavares de Sousa, Isadora Rosa, João Carvalho, Cláudia Camila Dias, Fernando Magro. Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays. Therapeutic Advances in Gastroenterology 2017; 10(9): 661 doi: 10.1177/1756283X17722915
|
| 3 |
Dario Sorrentino, Vu Nguyen, Carl Henderson, Adegabenga Bankole. Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases. Inflammatory Bowel Diseases 2016; 22(10): 2527 doi: 10.1097/MIB.0000000000000867
|
| 4 |
F. Magro, C. Rocha, A. I. Vieira, H. T. Sousa, I. Rosa, S. Lopes, J. Carvalho, C. C. Dias, J. Afonso. The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels. Therapeutic Advances in Gastroenterology 2018; 11 doi: 10.1177/1756284818796956
|
| 5 |
S Paul, Xavier Roblin. Response to Steenholdt. American Journal of Gastroenterology 2015; 110(11): 1624 doi: 10.1038/ajg.2015.328
|
| 6 |
Weiwei Jiang, Xuhang Li. Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy. Molecular Diagnosis & Therapy 2015; 19(3): 141 doi: 10.1007/s40291-015-0142-7
|
| 7 |
S. Ben‐Horin, B. Ungar, X. Roblin. Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors’ reply. Alimentary Pharmacology & Therapeutics 2017; 45(5): 760 doi: 10.1111/apt.13932
|
| 8 |
Francesca Nencini, Alessandra Vultaggio, Sara Pratesi, Daniele Cammelli, Monica Milla, Ginevra Fiori, Siro Bagnoli, Francesca Prignano, Sergio Romagnani, Enrico Maggi, Andrea Matucci. The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders. The Journal of Allergy and Clinical Immunology: In Practice 2018; 6(6): 2065 doi: 10.1016/j.jaip.2018.04.007
|
| 9 |
Joana Afonso, Susana Lopes, Raquel Gonçalves, Paulo Caldeira, Paula Lago, Helena Tavares de Sousa, Jaime Ramos, Ana Rita Gonçalves, Paula Ministro, Isadora Rosa, Ana Isabel Vieira, Rosa Coelho, Patrícia Tavares, João Soares, Ana Lúcia Sousa, Diana Carvalho, Paula Sousa, João Pereira da Silva, Tânia Meira, Filipa Silva Ferreira, Cláudia Camila Dias, Yehuda Chowers, Shomron Ben-Horin, Fernando Magro. Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays. Therapeutic Advances in Gastroenterology 2016; 9(6): 781 doi: 10.1177/1756283X16658223
|
| 10 |
Shomron Ben-Horin, Graham A Heap, Tariq Ahmad, HoUng Kim, TaekSang Kwon, Yehuda Chowers. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?. Expert Review of Gastroenterology & Hepatology 2015; 9(sup1): 27 doi: 10.1586/17474124.2015.1091307
|
| 11 |
Roni Weisshof, Bella Ungar, Alexandra Blatt, Aviva Dahan, Sigal Pressman, Matti Waterman, Uri Kopylov, Shomron Ben-Horin, Yehuda Chowers. Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2016; 22(7): 1655 doi: 10.1097/MIB.0000000000000797
|
| 12 |
Niels Vande Casteele, Hans Herfarth, Jeffry Katz, Yngve Falck-Ytter, Siddharth Singh. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. Gastroenterology 2017; 153(3): 835 doi: 10.1053/j.gastro.2017.07.031
|
| 13 |
Cátia Rocha, Paula Lago, Samuel Fernandes, Luís Correia, Francisco Portela, Ana Isabel Vieira, Marta Patita, Bruno Arroja, Paula Ministro, Catarina Alves, Cláudia Camila Dias, Fernando Magro. Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays. Therapeutic Advances in Gastroenterology 2020; 13 doi: 10.1177/1756284820965790
|
| 14 |
Inês Iria, Ruben R. G. Soares, Eduardo J. S. Brás, Virginia Chu, João Gonçalves, João P. Conde. Accurate and rapid microfluidic ELISA to monitor Infliximab titers in patients with inflammatory bowel diseases. The Analyst 2022; 147(3): 480 doi: 10.1039/D1AN01810H
|
| 15 |
Shiran Gerassy-Vainberg, Elina Starosvetsky, Renaud Gaujoux, Alexandra Blatt, Naama Maimon, Yuri Gorelik, Sigal Pressman, Ayelet Alpert, Haggai Bar-Yoseph, Tania Dubovik, Benny Perets, Adir Katz, Neta Milman, Meital Segev, Yehuda Chowers, Shai S. Shen-Orr. A personalized network framework reveals predictive axis of anti-TNF response across diseases. Cell Reports Medicine 2024; 5(1): 101300 doi: 10.1016/j.xcrm.2023.101300
|
| 16 |
J. Afonso, S. Lopes, R. Gonçalves, P. Caldeira, P. Lago, H. Tavares de Sousa, J. Ramos, A. R. Gonçalves, P. Ministro, I. Rosa, A. I. Vieira, C. C. Dias, F. Magro. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point‐of‐care quantitative test with two established ELISA assays. Alimentary Pharmacology & Therapeutics 2016; 44(7): 684 doi: 10.1111/apt.13757
|